In-111 Dtpa Solution
Loading...In-111 Dtpa Solution Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
In-111 DTPA is indicated for use in radionuclide cisternography
History
There is currently no drug history available for this drug.
Other Information
In-111 DTPA is supplied as a sterile, pyrogen-free, isotonic, aqueous solution that is buffered to pH 7 to 8. At calibration time, each milliliter contains 2.5 mCi of Pentetate Indium Disodium In-111 (no carrier-added) and sodium bicarbonate for pH adjustment.
Sources
In-111 Dtpa Solution Manufacturers
-
Anazaohealth Corporation
![In-111 Dtpa Solution [Anazaohealth Corporation]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
In-111 Dtpa Solution | Anazaohealth Corporation
Extreme care must be exercised to assure aseptic conditions in intrathecal injections. The maximum recommended intrathecal dose in the average patient (70kg) is 18.5 megabecquerels (500 microcuries). The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug preparations should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Storage and HandlingStore vial in its lead shield at a temperature of 5-30º C. Do not freeze
Login To Your Free Account